A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Some people are blessed to have a basement gym comprising everything they need to complete Monday back days, Wednesday push ...

Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...

Vitalik Buterin urges a 10X Ethereum scaling boost for L1 to enhance security, reduce L2 risks, and streamline application ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

As investors seek high-growth opportunities in the evolving crypto market, projects with strong fundamentals and real-world ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...

The XRP price surged 10% in the last 24 hours to trade at $2.82 as of 09:27 p.m. EST on trading volume that soared 60% to ...

Wall Street Pepe Closes Presale, Projecting 10x Returns Wall Street Pepe ($WEPE) has triumphantly wrapped up its presale ...

In this article, we have listed the best crypto presales to invest in 2025. These early-stage cryptos have a high potential ...

Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.